Media ReleaseFrom: The Lancet
The Lancet: Global improvement in cancer survival but international differences are still very wide
Cancer survival is generally increasing, even for some of the more deadly cancers such as liver and lung, according to the largest and most up-to-date study of population-based survival trends (2000–2014), covering countries that are home to more than two-thirds of the world’s population. But survival trends vary widely, and there are wide and persistent disparities between countries, particularly for some childhood cancers.
For example, while brain tumour survival in children has improved in many countries, 5-year survival is twice as high in Denmark and Sweden (around 80%) as in Mexico and Brazil (less than 40%) for children diagnosed as recently as 2014. This is likely to reflect the availability and quality of diagnostic and treatment services.
The CONCORD-3 study, published in The Lancet, analysed individual patient records from 322 cancer registries in 71 countries and territories to compare 5-year survival from diagnosis for more than 37.5 million adults (aged 15–99 years) and children (0–14 years) with one of 18 common cancers . These cancers represent three-quarters of all cancers diagnosed worldwide every year between 2000 and 2014. For the 10 cancers already included in the CONCORD-2 study, the researchers were able to examine trends over the 20-year period 1995¬–2014 .
Too many health ministries are flying blind on cancer control
The Organisation for Economic Co-operation and Development (OECD) is now using the CONCORD survival estimates to compare health system performance in 48 countries worldwide . However, in some parts of the world, estimation of survival is limited both by incomplete data and by legal or administrative obstacles to updating the cancer records with each patient’s date of death. For example, in Africa as many as 40% of records contained incomplete follow-up data, so survival trends could not be systematically assessed. 
Lead author Dr Claudia Allemani from the Cancer Survival Group at the London School of Hygiene & Tropical Medicine explains, “Continuous monitoring of global trends in cancer survival is crucial to assess the overall effectiveness of health systems world-wide, and to help policy-makers plan better strategies for cancer control. But, inadequate or unreliable data prevent governments from understanding the true nature and magnitude of the public health problems created by the growing cancer burden. This leaves governments poorly equipped to develop national cancer plans that will translate into real improvements in survival for patients.” 
She adds, “Governments must recognise cancer registries as efficient public health instruments that produce a continuous stream of valuable information on both the impact of cancer prevention strategies and the effectiveness of health systems, and at very low cost. In Europe, the cost of registering one case is less than the cost of a chest x-ray, and without this kind of information, health ministries are flying blind on cancer control.” 
Survival for most cancers remains highest in a handful of countries
After taking into account international differences in the age profile of cancer patients and the risk of death from other causes, survival for most cancers has been consistently high over the last 15 years in a handful of countries—the USA, Canada, Australia, New Zealand, Finland, Norway, Iceland, and Sweden.
For example, for women diagnosed with breast cancer in the USA and Australia between 2010 and 2014, 5-year survival is 90%, compared to 66% for women diagnosed in India. Within Europe, 5-year breast cancer survival increased to 85% or more in 16 countries including the UK, compared with a low of 71% in Eastern Europe (Russia).
In the UK, overall cancer survival is improving, with several cancers showing substantial increases in 5-year survival between 2000 and 2014, including breast (80% to 86%), prostate (82% to 89%), rectum (55% to 63%) and colon (52% to 60%)—reflecting better cancer management. However, adults with cancer continue to have lower 5-year survival than in other comparable countries for several common cancers, including myeloid malignancies (such as acute myeloid leukaemia) and adult brain cancer.
Denmark is closing the gap with other Nordic countries
Cancer survival has improved markedly in Denmark—so that, for the majority of cancers, the Danes have almost caught up with their Nordic counterparts—including prostate (64% in 2000–2004 to 86% in 2010–2014), lung (10% to 17%), oesophagus (8% to 14%), and rectum (53% to 65%). These rapid improvements over the past 15 years have been driven by better investment, accelerated patient pathways, with public monitoring of hospitals’ compliance with waiting times.
The deadliest cancers
While liver and lung cancers remain rapidly lethal in high- and low-income countries alike, the past two decades have seen some important progress in 5-year survival in several nations. Liver cancer survival increased by more than 10% in Korea (11% to 27%), Sweden (5% to 17%), Portugal (8% to 19%), and Norway (6% to 19%). Similarly, lung cancer survival increased by 5–10% in 21 countries including the UK (7% to 13%) between 1995 and 2014, with most progress seen in China (8% to 20%), Japan (23% to 33%), and Korea (10% to 25%).
But not all major cancers have seen such improvements. Even in 2014, pancreatic cancer remained highly lethal in all countries, with 5-year survival typically less than 15%. “Greater international efforts are needed to understand the risk factors for this rapidly lethal cancer and to improve prevention, early diagnosis, and treatment”, says co-author Professor Michel Coleman from the London School of Hygiene & Tropical Medicine. 
Gastrointestinal cancers far less lethal in south-east Asia
In parts of south-east Asia, 5-year survival from stomach cancer is more than twice as high as in most other countries, including the USA (33%) and the UK (21%). Between 2000–2004 and 2010–2014, 5-year survival increased from 49% to 69% in South Korea and from 51% to 60% in Japan. These faster improvements in survival could be due to long-standing population-based endoscopic screening programmes, and the authors suggest that screening should be part of national control plans in countries like Russia, where gastrointestinal cancers are a huge public health problem.
In contrast, survival for melanoma of the skin in south-east Asia is generally lower than the rest of the world, possibly reflecting lower public awareness and a more prevalent lethal subtype (acral lentiginous melanoma).
Wide gulf in survival from childhood cancers
The analysis highlights that survival differences in childhood brain cancer are particularly wide, ranging from less than 40% during 2010-2014 in Brazil and Mexico to around 80% in Sweden, Denmark, and Slovakia. Despite increases in most countries since the mid-1990s, 5-year survival for children diagnosed with the most common type of childhood cancer (acute lymphoblastic leukaemia; ALL) also varies substantially worldwide, indicating major deficiencies in the diagnosis and treatment of a disease that is generally considered as curable. 5-year survival is higher than 90% in several countries, including Canada, the USA and nine European countries (e.g., Finland, the UK, and Denmark), but it remains below 60% in China, Mexico, and Ecuador.
Professor Coleman explains, “Despite improvements in awareness, services, and treatments, cancer still kills more than 100,000 children every year worldwide. If we are to ensure that more children survive cancer for longer, we need reliable data on the cost and effectiveness of health services in all countries, to compare the impact of strategies in managing childhood cancer.” 
Better data needed to monitor cancer survival trends
The authors conclude by calling for cancer registries to be given adequate resources to register all patients and to link the registry data to up-to-date death records.
Writing in a linked Comment, Professor Richard Sullivan from the King’s Health Partners Comprehensive Cancer Centre in London says, “Despite more than 20 years of advocacy for national and international funding to support the establishment of fully functional cancer registries, both domestic and global political support and funding remain woeful. Considering the billions of dollars poured into research each year, the fact that the one universal need for all countries—cancer intelligence from national and regional registries—cannot be properly supported reflects both political myopia and distorted priorities... National and regional governments must recognise that population-based cancer registries are key policy tools, both to monitor the impact of cancer prevention strategies, and to evaluate the effectiveness of the health system for all patients diagnosed with cancer.”
NOTES TO EDITORS
This study was funded by Centers for Disease Control and Prevention (USA); Swiss Re; Swiss Cancer Research foundation; Swiss Cancer League; Institut National du Cancer (France); La Ligue Contre le Cancer (France); Rossy Family Foundation (Canada); National Cancer Institute (USA); the Susan G Komen Foundation (USA), and the American Cancer Society
 Oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, together with brain tumours, leukaemias, and lymphomas in both adults and children.
 CONCORD-2 http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(14)62038-9.pdf
 The survival estimates were directly derived from the records of individuals diagnosed with cancer. No attempt was made to model cancer survival in countries or regions where population-based cancer registration data were not available.
 Quotes direct from authors and cannot be found in text of Article
 The figures for 1995-1999 are not included in the paper, but can be found in CONCORD-2 http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(14)62038-9.pdf